These findings highlight potential differences in the genetic landscape of GC between H/L and NHW patients, particularly with lower TP53 mutation prevalence in H/L individuals, which may have implications for tumor biology, disease progression, and targeted treatment approaches. This evidence concerns the gene TP53 and neoplasm.